Skip Navigation Links
Phase 2/3 Adaptive Study of VX-147 in Adults With APOL1- Mediated Proteinuric Kidney Disease
Overall Recruitment Status: Enrollment not started
Official Title
A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Subjects Aged 18 Years and Older With APOL1-mediated Proteinuric Kidney Disease
Region Sponsors
California - Northern
Vertex Pharmaceuticals Incorporated
Acronym KP IRB No.
Study Type Phase
Clinical Trial Phase II
Study Population Description
(Adult, Older Adult) with Proteinuric Kidney Disease
The purpose of this study is to evaluate the efficacy, safety, tolerability and pharmacokinetics (PK) of VX-147 in participants aged 18 years and older with apolipoprotein L1 (APOL1)-mediated proteinuric kidney disease.
Detailed Description
Gender Age Limit
Male & Female 18 - 65 years
Inclusion Criteria
  • APOL1 genotype of G1/G1, G2/G2, or G1/G2
  • Proteinuric kidney disease
Exclusion Criteria
  • Solid organ or bone marrow transplant
  • Uncontrolled hypertension
  • Diagnosis of diabetes mellitus
  • Known underlying cause of kidney disease including but not limited to sickle cell disease
  • Please contact study team, other protocol defined Inclusion/Exclusion criteria apply

Keywords and/or Specific Medical Conditions
  • Kidney Diseases
  • VX21-147-301
  • Urologic Diseases
  • Nephrology
KP Clinical Facility
  • Sacramento Medical Center
Clinical Area
  • Nephrology

Principal Investigator:
Anthony Alvarado , MD
Contact Information:
- Victoria Z Khomits-Koval, RN
-Sacramento Medical Center

Do you want to receive
Email Alerts?

Sign Up Here!

Regional Research Sites: